BRANFORD, Conn., April 27, 2009 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced that the Company's FORE-SIGHT(r) Absolute Cerebral Oximeter now has the capability to interface with the Philips Healthcare IntelliVue monitoring system. FORE-SIGHT absolute cerebral tissue oxygen saturation (SctO2) measured values can be transmitted through the Philips VueLink module and displayed in real-time on the IntelliVue patient monitor display screen.
IntelliVue monitors collect, combine, and cross-reference physiologic data for comparison and storage. This patient data integration reduces the number of displays, control, alarm and documentation points at the bedside - providing a clear view of patient information that supports clinical thought processes. FORE-SIGHT's new communication ability with Philips IntelliVue allows absolute SctO2 data to be displayed with a wide array of critical care and operating room physiologic measurements, offering convenient central viewing of decision support variables.
The FORE-SIGHT Absolute Cerebral Oximeter is compatible with the many Philips IntelliVue and CMS Patient Monitors already installed worldwide. Current users of these Philips systems can simply connect the FORE-SIGHT monitor to existing systems via the VueLink AUXPLUS module.
Andrew E. Kersey, President and CEO of CASMED, stated, "CASMED is very pleased to announce interface capability with Philips Healthcare, a worldwide leader in acute-care patient monitoring systems and critical-care clinical information systems. With the capability to interface FORE-SIGHT via the VueLink module, we are able to provide clinicians a single display of reference that integrates our critical data with additional physiological parameters, ventilators, anesthesia machines and infusion devices into a single bedside display - providing a comprehensive picture of patient status."
About CASMED(r) - Monitoring What's Vital
CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the first cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.
The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter, the bedside patient monitoring line of vital signs and cardio-respiratory monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.
For further information regarding CAS Medical Systems, Inc., visit the Company's website at www.casmed.com.
The CAS Medical Systems, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4675
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, commercialization and technological difficulties, the impact of actions and events involving key customers and vendors, and other risks detailed in the Company's Form 10-K for the year ended December 31, 2008 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.